These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 24998285)

  • 1. India’s IP appellate board upholds Pfizer’s detrol® patent.
    Pharm Pat Anal; 2014 May; 3(3):223. PubMed ID: 24998285
    [No Abstract]   [Full Text] [Related]  

  • 2. India's patent ecosystem - encouraging strong patents or discouraging innovation?
    Harrison C
    Nat Rev Drug Discov; 2013 Oct; 12(10):732-3. PubMed ID: 24080690
    [No Abstract]   [Full Text] [Related]  

  • 3. US court invalidates Pfizer’s Celebrex® patent.
    Pharm Pat Anal; 2014 May; 3(3):224. PubMed ID: 25129896
    [No Abstract]   [Full Text] [Related]  

  • 4. Novartis challenges India's drug patent laws in Supreme Court.
    Billingsley M
    BMJ; 2012 Feb; 344():e1279. PubMed ID: 22354594
    [No Abstract]   [Full Text] [Related]  

  • 5. India's new patent laws may still hurt generic drug supplies.
    Chatterjee P
    Lancet; 2005 Apr 16-22; 365(9468):1378. PubMed ID: 15841559
    [No Abstract]   [Full Text] [Related]  

  • 6. Changes to India's patent law may deny cheap drugs to millions.
    Mudur G
    BMJ; 2005 Mar; 330(7493):692. PubMed ID: 15790640
    [No Abstract]   [Full Text] [Related]  

  • 7. Legal challenge to India's patent laws threatens access to generic drugs, says charity.
    Moszynski P
    BMJ; 2011 Sep; 343():d5753. PubMed ID: 21908529
    [No Abstract]   [Full Text] [Related]  

  • 8. India's IP snub.
    Jayaraman KS
    Nat Biotechnol; 2008 Apr; 26(4):362. PubMed ID: 18392000
    [No Abstract]   [Full Text] [Related]  

  • 9. Intellectual property. Challenges to India's pharmaceutical patent laws.
    Sampat BN; Shadlen KC; Amin TM
    Science; 2012 Jul; 337(6093):414-5. PubMed ID: 22767892
    [No Abstract]   [Full Text] [Related]  

  • 10. India's rejection of Novartis's patent is but a small step in the right direction.
    Bhaumik S
    BMJ; 2013 Apr; 346():f2412. PubMed ID: 23596223
    [No Abstract]   [Full Text] [Related]  

  • 11. Drugmakers struggle with Indian patents.
    Cancer Discov; 2012 Dec; 2(12):OF5. PubMed ID: 23230206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. India's patent laws under pressure.
    Roderick P; Pollock AM
    Lancet; 2012 Sep; 380(9846):e2-4. PubMed ID: 22988579
    [No Abstract]   [Full Text] [Related]  

  • 13. Will the Modi government succumb to US and industry pressure to modify its pro-access pharmaceutical patent policy?
    Baker BK
    Expert Opin Ther Pat; 2015 Jun; 25(6):625-8. PubMed ID: 25704359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent developments in health law. India's evolving patent laws and WTO obligations: the rejection of Abbott Laboratories' application for a new Kaletra patent.
    Chilton A
    J Law Med Ethics; 2011; 39(2):296-300. PubMed ID: 21710799
    [No Abstract]   [Full Text] [Related]  

  • 15. Impact of India's new patents law 2005: a physician's perspective.
    Lele RD
    J Assoc Physicians India; 2005 Aug; 53():671-5. PubMed ID: 16398073
    [No Abstract]   [Full Text] [Related]  

  • 16. India's patent laws and the multinational pharmaceutical industry.
    Srinivasan S; Bharadwaj K
    Natl Med J India; 2013; 26(3):128-32. PubMed ID: 24476157
    [No Abstract]   [Full Text] [Related]  

  • 17. Is tolterodine (Detrol) or oxybutynin (Ditropan) the best for treatment of urge urinary incontinence?
    Blonski J
    J Fam Pract; 2001 Dec; 50(12):1017. PubMed ID: 11742595
    [No Abstract]   [Full Text] [Related]  

  • 18. Is extended-release oxybutynin (Ditropan XL) or tolterodine (Detrol) more effective in the treatment of an overactive bladder?
    Hartnett NM; Saver BG
    J Fam Pract; 2001 Jul; 50(7):571. PubMed ID: 11485700
    [No Abstract]   [Full Text] [Related]  

  • 19. Detrol LA and Diropan XL for overactive bladder.
    Med Lett Drugs Ther; 2001 Apr; 43(1101):28. PubMed ID: 11283473
    [No Abstract]   [Full Text] [Related]  

  • 20. Big Pharma vs India’s Patent Office.
    Pharm Pat Anal; 2012 Nov; 1(5):529. PubMed ID: 24236921
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.